Responses
Regular and Young Investigator Award Abstracts
Cellular Therapies
228 Engineered human IL-2/IL-2Rß orthogonal pairs selectively enhance anti-GPC3 CAR T cells in vivo to drive complete responses in solid epithelial tumor models
Compose a Response to This Article
Other responses
No responses have been published for this article.
